Abstract

Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD)
Parameswaran Hari ... Yubin Kang
Blood | VOL. 138
Parameswaran Hari, et. al.Parameswaran Hari ... Yubin Kang
05 Nov 2021
The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma
Robert A Kyle ...
Blood | VOL. 138
Robert A Kyle, et. al.Robert A Kyle ...
05 Nov 2021
Prognostic Factors for Early (5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes
Suzanne R Hayman ... Taxiarchis Kourelis
Blood | VOL. 138
Suzanne R Hayman, et. al.Suzanne R Hayman ... Taxiarchis Kourelis
05 Nov 2021
The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma
Suzanne R Hayman ... Rahma M Warsame
Blood | VOL. 138
Suzanne R Hayman, et. al.Suzanne R Hayman ... Rahma M Warsame
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Luisa Corrêa De Araujo Koury ... Eduardo M Rego
Blood | VOL. -
Luisa Corrêa De Araujo Koury, et. al.Luisa Corrêa De Araujo Koury ... Eduardo M Rego
28 May 2024
Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle.
Carys S Johnson ... Elisa Laurenti
Blood | VOL. -
Carys S Johnson, et. al.Carys S Johnson ... Elisa Laurenti
28 May 2024
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
Berit J Brinkmann ... Sascha Dietrich
Blood | VOL. -
Berit J Brinkmann, et. al.Berit J Brinkmann ... Sascha Dietrich
28 May 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Matthew J Frigault ... Marcela V Maus
Blood | VOL. -
Matthew J Frigault, et. al.Matthew J Frigault ... Marcela V Maus
23 May 2024
View more papers